263 related articles for article (PubMed ID: 29193572)
1. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
[TBL] [Abstract][Full Text] [Related]
2. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Li L; Shen J; Bala MM; Busse JW; Ebrahim S; Vandvik PO; Rios LP; Malaga G; Wong E; Sohani Z; Guyatt GH; Sun X
BMJ; 2014 Apr; 348():g2366. PubMed ID: 24736555
[TBL] [Abstract][Full Text] [Related]
3. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
4. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
5. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
Nauck MA; Meier JJ; Schmidt WE
Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
[No Abstract] [Full Text] [Related]
6. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks.
Chai S; Yu S; Yang Z; Wu S; Gao L; Wang H; Zhang Y; Zhan S; Ji L; Sun F
BMJ Open Diabetes Res Care; 2019; 7(1):e000728. PubMed ID: 31641525
[TBL] [Abstract][Full Text] [Related]
7. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
[TBL] [Abstract][Full Text] [Related]
8. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
9. An updated review on cancer risk associated with incretin mimetics and enhancers.
Tseng CH; Lee KY; Tseng FH
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2015; 33(1):67-124. PubMed ID: 25803196
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Incretin-Based Therapies in Patients With Type 2 Diabetes Mellitus and CKD: A Systematic Review and Meta-analysis.
Howse PM; Chibrikova LN; Twells LK; Barrett BJ; Gamble JM
Am J Kidney Dis; 2016 Nov; 68(5):733-742. PubMed ID: 27528374
[TBL] [Abstract][Full Text] [Related]
11. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Montvida O; Green JB; Atherton J; Paul SK
Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
[TBL] [Abstract][Full Text] [Related]
12. Incretin based treatments and mortality in patients with type 2 diabetes: systematic review and meta-analysis.
Liu J; Li L; Deng K; Xu C; Busse JW; Vandvik PO; Li S; Guyatt GH; Sun X
BMJ; 2017 Jun; 357():j2499. PubMed ID: 28596247
[No Abstract] [Full Text] [Related]
13. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials.
Singh AK; Gangopadhyay KK; Singh R
Expert Rev Clin Pharmacol; 2020 Apr; 13(4):461-468. PubMed ID: 32129106
[TBL] [Abstract][Full Text] [Related]
14. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials.
Abd El Aziz M; Cahyadi O; Meier JJ; Schmidt WE; Nauck MA
Diabetes Obes Metab; 2020 Apr; 22(4):699-704. PubMed ID: 31750601
[TBL] [Abstract][Full Text] [Related]
15. The cardiovascular effect of incretin-based therapies among type 2 diabetes: a systematic review and network meta-analysis.
Wu S; Cipriani A; Yang Z; Yang J; Cai T; Xu Y; Quan X; Zhang Y; Chai S; Sun F; Zhan S
Expert Opin Drug Saf; 2018 Mar; 17(3):243-249. PubMed ID: 29320889
[TBL] [Abstract][Full Text] [Related]
16. [Incretin-based antidiabetic treatment and diseases of the pancreas (pancreatitis, pancreas carcinoma)].
Jermendy G
Orv Hetil; 2016 Apr; 157(14):523-8. PubMed ID: 27017851
[TBL] [Abstract][Full Text] [Related]
17. Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies.
Boniol M; Franchi M; Bota M; Leclercq A; Guillaume J; van Damme N; Corrao G; Autier P; Boyle P
Diabetes Care; 2018 Feb; 41(2):286-292. PubMed ID: 29146599
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis.
Amori RE; Lau J; Pittas AG
JAMA; 2007 Jul; 298(2):194-206. PubMed ID: 17622601
[TBL] [Abstract][Full Text] [Related]
19. Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis.
Waldrop G; Zhong J; Peters M; Goud A; Chen YH; Davis SN; Mukherjee B; Rajagopalan S
J Diabetes Complications; 2018 Jan; 32(1):113-122. PubMed ID: 29074120
[TBL] [Abstract][Full Text] [Related]
20. A systematic review and meta-analysis of observational studies of the association between the use of incretin-based therapies and the risk of pancreatic cancer.
Hidayat K; Zhou YY; Du HZ; Qin LQ; Shi BM; Li ZN
Pharmacoepidemiol Drug Saf; 2023 Feb; 32(2):107-125. PubMed ID: 36224724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
